Assembly Biosciences Inc
ASMB32.730USD
-3.450-9.54%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
517.69MMarket Cap
LossP/E TTM
More Details of Assembly Biosciences Inc Company
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Assembly Biosciences Inc Info
Ticker SymbolASMB
Company nameAssembly Biosciences Inc
IPO dateDec 17, 2010
CEO- -
Number of employees73
Security typeOrdinary Share
Fiscal year-endDec 17
AddressTwo Tower Place
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone18334094583
Websitehttps://www.assemblybio.com/
Ticker SymbolASMB
IPO dateDec 17, 2010
CEO- -
Company Executives of Assembly Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John G. McHutchison, M.D.
Dr. John G. McHutchison, M.D.
Director
Director
16.60K
+18.30%
Mr. Jason A. Okazaki
Mr. Jason A. Okazaki
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
14.11K
+55.95%
Dr. Nicole S. White, Ph.D.
Dr. Nicole S. White, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
7.82K
+78.83%
Sir Michael Houghton, Esq.
Sir Michael Houghton, Esq.
Independent Director
Independent Director
3.20K
--
Mr. Anthony E. (Tony) Altig
Mr. Anthony E. (Tony) Altig
Independent Director
Independent Director
666.00
--
Ms. Jeanette Bjorkquist
Ms. Jeanette Bjorkquist
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Ms. Gina Consylman, CPA
Ms. Gina Consylman, CPA
Independent Director
Independent Director
--
--
Dr. Tomas Cihlar, Ph.D.
Dr. Tomas Cihlar, Ph.D.
Director
Director
--
--
Mr. Robert D. Cook, II
Mr. Robert D. Cook, II
Director
Director
--
--
Dr. William E. Delaney, IV, Ph.D.
Dr. William E. Delaney, IV, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John G. McHutchison, M.D.
Dr. John G. McHutchison, M.D.
Director
Director
16.60K
+18.30%
Mr. Jason A. Okazaki
Mr. Jason A. Okazaki
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
14.11K
+55.95%
Dr. Nicole S. White, Ph.D.
Dr. Nicole S. White, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
7.82K
+78.83%
Sir Michael Houghton, Esq.
Sir Michael Houghton, Esq.
Independent Director
Independent Director
3.20K
--
Mr. Anthony E. (Tony) Altig
Mr. Anthony E. (Tony) Altig
Independent Director
Independent Director
666.00
--
Ms. Jeanette Bjorkquist
Ms. Jeanette Bjorkquist
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
28.48%
Janus Henderson Investors
8.48%
Farallon Capital Management, L.L.C.
7.76%
RA Capital Management, LP
6.45%
Commodore Capital LP
6.32%
Other
42.50%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
28.48%
Janus Henderson Investors
8.48%
Farallon Capital Management, L.L.C.
7.76%
RA Capital Management, LP
6.45%
Commodore Capital LP
6.32%
Other
42.50%
Shareholder Types
Shareholders
Proportion
Corporation
28.48%
Hedge Fund
20.48%
Investment Advisor/Hedge Fund
15.66%
Investment Advisor
7.59%
Venture Capital
6.53%
Individual Investor
3.84%
Private Equity
3.74%
Research Firm
0.37%
Other
13.32%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
108
8.01M
21.49%
--
2025Q3
112
8.01M
22.74%
+4.92M
2025Q2
88
945.80K
19.27%
-27.31K
2025Q1
87
977.81K
19.53%
-509.85K
2024Q4
89
992.85K
21.13%
-47.22K
2024Q3
90
1.04M
28.47%
-145.58K
2024Q2
90
1.18M
20.50%
+528.82K
2024Q1
95
655.99K
27.78%
-867.09K
2023Q4
107
730.66K
346.30%
-82.66K
2023Q3
122
806.09K
44.51%
-78.15K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
4.51M
33.97%
+2.30M
+103.91%
Aug 08, 2025
Farallon Capital Management, L.L.C.
1.14M
8.6%
+1.14M
--
Aug 08, 2025
Commodore Capital LP
1.00M
7.54%
+1.00M
--
Aug 08, 2025
Schornstein (Alexander)
543.52K
4.1%
-184.59K
-25.35%
Aug 18, 2025
The Vanguard Group, Inc.
253.82K
1.91%
+37.84K
+17.52%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
iShares Core S&P Total U.S. Stock Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
Proportion0.03%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Date
Type
Ratio
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
FAQs
Who are the top five shareholders of Assembly Biosciences Inc?
The top five shareholders of Assembly Biosciences Inc are:
Gilead Sciences Inc holds 4.51M shares, accounting for 33.97% of the total shares.
Farallon Capital Management, L.L.C. holds 1.14M shares, accounting for 8.60% of the total shares.
Commodore Capital LP holds 1.00M shares, accounting for 7.54% of the total shares.
Schornstein (Alexander) holds 543.52K shares, accounting for 4.10% of the total shares.
The Vanguard Group, Inc. holds 253.82K shares, accounting for 1.91% of the total shares.
Gilead Sciences Inc holds 4.51M shares, accounting for 33.97% of the total shares.
Farallon Capital Management, L.L.C. holds 1.14M shares, accounting for 8.60% of the total shares.
Commodore Capital LP holds 1.00M shares, accounting for 7.54% of the total shares.
Schornstein (Alexander) holds 543.52K shares, accounting for 4.10% of the total shares.
The Vanguard Group, Inc. holds 253.82K shares, accounting for 1.91% of the total shares.
What are the top three shareholder types of Assembly Biosciences Inc?
The top three shareholder types of Assembly Biosciences Inc are:
Gilead Sciences Inc
Janus Henderson Investors
Farallon Capital Management, L.L.C.
Gilead Sciences Inc
Janus Henderson Investors
Farallon Capital Management, L.L.C.
How many institutions hold shares of Assembly Biosciences Inc (ASMB)?
As of 2025Q4, 108 institutions hold shares of Assembly Biosciences Inc, with a combined market value of approximately 8.01M, accounting for 21.49% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.25%.
What is the biggest source of revenue for Assembly Biosciences Inc?
In --, the -- business generated the highest revenue for Assembly Biosciences Inc, amounting to -- and accounting for --% of total revenue.
